Savara's FDA Decision Date Is Not This Saturday. It Moved to Nov. 22 Four Months Ago.

by Ellis Vance · August 17, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

Anyone building a small-cap biotech catalyst calendar for this week from some of the free published sources would have penciled in Saturday, Aug. 22, as the day the Food and Drug Administration rules on Savara Inc.'s inhaled therapy for a rare lung disease. Savara's own disclosures say that date stopped being operative on April 15.

In a release datelined Langhorne, Pa., April 15, 2026, and carried on Business Wire, Savara said the FDA had extended the review period for its molgramostim inhalation solution biologics license application by three months, moving the target action date from Aug. 22, 2026 to Nov. 22, 2026. The company attributed the change to a procedural determination rather than a substantive objection: the agency, it said, concluded that Savara's responses to recent information requests constituted a major amendment to the BLA, which triggered the three-month extension. The same release stated that the agency did not cite any safety, efficacy or manufacturing concerns in its correspondence. A note on what we read. Savara's own investor-relations page for that release returned a 403 error to us, and we did not locate an SEC-filed version of it, so we worked from two independent reproductions of the Business Wire text — Drugs.com and StockTitan, the latter timestamped 4:05 p.m. ET on April 15 — which carry identical wording on the extension, on the major-amendment determination and on the absence of cited concerns. The November 22 date does not rest on those reproductions alone: Savara's own second-quarter release, issued through Business Wire on Aug. 11 and read directly, states that the MOLBREEVI BLA PDUFA target action date is set for Nov. 22, 2026.

The Aug. 22 date was real once. On Feb. 20, 2026, Savara announced that the FDA had filed the MOLBREEVI BLA in autoimmune pulmonary alveolar proteinosis and granted it Priority Review with a PDUFA action date of Aug. 22, 2026. MarketBeat's own entry stamps its August date to that Feb. 20 announcement, which suggests where the surviving calendar entries came from.

We read three published FDA calendars on Monday morning, before the opening bell, and it is worth being literal about what each one says. MarketBeat's upcoming FDA dates page runs columns headed Main Company, Current Price, Target Date, Drug, Status and Event. Savara appears on it twice. One row reads SVRA, $5.38, Target Date August 22, 2026, drug MOLBREEVI, status BLA, with an Event field beginning "2/20/2026 - PDUFA Date" and summarising the Priority Review announcement. A second row reads SVRA, $5.38, Target Date November 22, 2026, drug Molgramostim (IMPALA-2), with an Event field beginning "4/15/2026 - PDUFA Date" and summarising the three-month extension. The dates inside that Event column are the dates the announcements were made, not additional target action dates; MarketBeat therefore carries the corrected date and the superseded one side by side, filed under two different drug names, and a reader sorting by nearest date meets the wrong one first.

BiopharmaWatch's PDUFA calendar is the one that is simply behind. Its row for Savara (SVRA) gives the drug as MOLBREEVI (molgramostim inhalation solution) for autoimmune pulmonary alveolar proteinosis, and the value in its column headed PDUFA Date is 2026-08-22. There is no Savara entry for November 22 anywhere on that page. The third calendar, pdufa.bio, has it right: it lists Savara's MOLBREEVI only at 2026-11-22, and shows no Savara entry in the Aug. 17 to Sept. 15 window, where its listings include Capricor on Aug. 22, Ultragenyx on Aug. 23 and Jazz on Aug. 25. That is the full extent of the survey — three sources, one wrong, one both right and wrong at once, one right.

Savara has not been quiet about the correct date. Its second-quarter release, issued Aug. 11, states plainly that the MOLBREEVI BLA PDUFA target action date is set for Nov. 22, 2026. We found no Savara press release dated after Aug. 11 on the news list published by StockAnalysis, which showed the Aug. 11 earnings item as the most recent company announcement ahead of Monday's open.

What the FDA means by a major amendment is spelled out in the agency's PDUFA reauthorization performance goals and procedures for fiscal years 2023 through 2027. That document provides that a major amendment to an original application, submitted at any point during the review cycle, may extend the goal date by three months, and it gives as examples a major new clinical safety or efficacy study report, a major re-analysis of previously submitted studies, or the submission of a risk evaluation and mitigation strategy with elements to assure safe use that was not in the original filing. The same section states that only one extension can be given per review cycle.

That last clause is the part worth holding onto. Under the goals letter's own terms, the November date cannot be moved again by a second major-amendment extension inside this review cycle. It says nothing about whether the agency approves, and an extension is a change to a clock, not a verdict on an application. Savara's characterization is that no safety, efficacy or manufacturing concern accompanied the letter; that is the company's account of the correspondence, which is not public.

The underlying asset is a single one. Molgramostim is an inhaled formulation of GM-CSF aimed at autoimmune pulmonary alveolar proteinosis, a rare condition in which the patient's own antibodies neutralize GM-CSF, leaving alveolar macrophages unable to clear surfactant. Surfactant accumulates in the air sacs, gas transfer degrades, and patients present with breathlessness, cough and fatigue, according to the disease description in Savara's February release. The company's second-quarter release describes delivery via the investigational eFlow Nebulizer System made by PARI Pharma GmbH.

The August financials show a company spending as though a launch is coming. Savara reported a second-quarter net loss of $40.2 million, or 16 cents per share, against $30.4 million and 14 cents a year earlier, on 253,569,891 weighted average shares. Research and development expense rose about 6 percent, to $21.95 million from $20.75 million. General and administrative expense — the release's own line-item label — was the line that moved: $18.99 million against $10.66 million a year earlier, an increase of about 78 percent by our calculation, which the company tied to personnel and commercial activities as it builds the infrastructure to support a launch. Cash, cash equivalents and short-term investments stood at $173.0 million at June 30.

"While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity," Matt Pauls, Savara's chair and chief executive officer, said in the Aug. 11 release. "Our focus is on the potential launch of MOLBREEVI in the U.S., supported by a strong balance sheet to ensure commercial readiness."

The same release says the company has access to up to approximately $150 million in non-dilutive capital upon FDA approval of MOLBREEVI. The conditioning language is the point: that capital is described as contingent on approval, so it is not available to fund the wait. The release does not name the provider of that capital or set out its terms, and we draw no inference from that; companies routinely disclose financing counterparties in the credit agreement itself rather than in an earnings release. Outside the United States, Savara said its marketing authorization applications are under review by the European Medicines Agency, with a decision expected in the first quarter of 2027, and by the U.K.'s MHRA, with a decision expected in the fourth quarter of 2026.

For scale, StockAnalysis shows SVRA at $5.38 as of the 4 p.m. ET close on Friday, Aug. 14, up 11 cents or 2.09 percent from Thursday's $5.27 close, with a market capitalization of $1.37 billion on 254.14 million shares outstanding and a 52-week range of $2.68 to $7.01. The last quote we captured before writing was a premarket print of $5.43 on the same page, stamped 7:12 a.m. ET Monday, Aug. 17. That is a premarket figure and nothing more; Monday's regular session has since opened, and no price in this article reflects it.

One small scheduling artifact is worth noting for anyone marking a diary. Both the original and the revised goal dates land on weekends: on the 2026 calendar, Aug. 22 falls on a Saturday and Nov. 22 on a Sunday. Under the FDA's own goals letter these are dates by which the agency aims to complete its review and act, not scheduled announcement times, so a weekend date does not imply anything about when a decision would become public.

The risks here are the ordinary ones for a company whose value rests on one regulatory outcome, and they should be stated plainly. The FDA is not obliged to approve MOLBREEVI on Nov. 22 or at all; it can issue a complete response letter, and the goal date is a performance target rather than a guarantee of action. Savara is loss-making, reported a $77.5 million net loss for the first half, and its stated non-dilutive capital is contingent on an approval that has not happened. A net loss is not the same figure as cash used in operations, and readers sizing runway should work from the cash flow statement rather than from the loss line.

The practical takeaway is narrower than the drug: when a catalyst date is the whole reason a name is on a watchlist, the company's own most recent disclosure is the only calendar that counts. In this case one of the three published calendars we read on Monday morning had not caught up with a four-month-old correction and a second was still showing the superseded date beside the right one, and the difference between the stale entry and Savara's own disclosure is three months of waiting.